Id: acc0786
Group: 2sens
Protein: Src
Gene Symbol: SRC
Protein Id: P12931
Protein Name: SRC_HUMAN
PTM: phosphorylation
Site: Tyr416
Site Sequence: DFGLARLIEDNEYTARQGAKF
Disease Category: Cancer
Disease: Prostate Cancer
Disease Subtype:
Disease Cellline: PC3-M
Disease Info:
Drug: apigenin
Drug Info: "Apigenin is a naturally occurring flavonoid compound with demonstrated potential as an antifungal agent in the preparation of drugs against human fungal infections, and it is also being researched in drug delivery systems such as solid lipid nanoparticles (APG-SLNP) to enhance stability and bioavailability. "
Effect: modulate
Effect Info: "Apigenin inhibits prostate carcinogenesis by suppressing the phosphorylation of Smad2/3, Src, FAK and Akt."
Note:
Score: 4.0
Pubmed(PMID): 23359392
Sentence Index:
Sentence:

Sequence & Structure:

MGSNKSKPKDASQRRRSLEPAENVHGAGGGAFPASQTPSKPASADGHRGPSAAFAPAAAEPKLFGGFNSSDTVTSPQRAGPLAGGVTTFVALYDYESRTETDLSFKKGERLQIVNNTEGDWWLAHSLSTGQTGYIPSNYVAPSDSIQAEEWYFGKITRRESERLLLNAENPRGTFLVRESETTKGAYCLSVSDFDNAKGLNVKHYKIRKLDSGGFYITSRTQFNSLQQLVAYYSKHADGLCHRLTTVCPTSKPQTQGLAKDAWEIPRESLRLEVKLGQGCFGEVWMGTWNGTTRVAIKTLKPGTMSPEAFLQEAQVMKKLRHEKLVQLYAVVSEEPIYIVTEYMSKGSLLDFLKGETGKYLRLPQLVDMAAQIASGMAYVERMNYVHRDLRAANILVGENLVCKVADFGLARLIEDNEYTARQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILLTELTTKGRVPYPGMVNREVLDQVERGYRMPCPPECPESLHDLMCQCWRKEPEERPTFEYLQAFLEDYFTSTEPQYQPGENL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
SRC DASATINIB SRC inhibitor 4 - acute lymphoblastic leukemia DailyMed
DailyMed
SRC DASATINIB SRC inhibitor 4 Unknown status acute lymphoblastic leukemia ClinicalTrials
SRC DASATINIB SRC inhibitor 4 - chronic myelogenous leukemia DailyMed
DailyMed
SRC DASATINIB SRC inhibitor 4 Completed chronic myelogenous leukemia ClinicalTrials
ClinicalTrials
SRC DASATINIB SRC inhibitor 4 Unknown status chronic myelogenous leukemia ClinicalTrials
SRC DASATINIB SRC inhibitor 4 Recruiting chronic myelogenous leukemia ClinicalTrials
ClinicalTrials
ClinicalTrials
SRC VANDETANIB Tyrosine-protein kinase SRC inhibitor 4 - neoplasm ATC
SRC DASATINIB SRC inhibitor 4 - neoplasm ATC
SRC TIRBANIBULIN Tyrosine-protein kinase SRC inhibitor 4 Completed actinic keratosis ClinicalTrials
ClinicalTrials
SRC TIRBANIBULIN Tyrosine-protein kinase SRC inhibitor 4 Recruiting actinic keratosis ClinicalTrials
SRC TIRBANIBULIN Tyrosine-protein kinase SRC inhibitor 4 - actinic keratosis FDA
DailyMed
EMA
SRC TIRBANIBULIN Tyrosine-protein kinase SRC inhibitor 4 Withdrawn actinic keratosis ClinicalTrials
SRC VANDETANIB Tyrosine-protein kinase SRC inhibitor 4 - thyroid carcinoma DailyMed
SRC VANDETANIB Tyrosine-protein kinase SRC inhibitor 4 - thyroid neoplasm EMA
SRC DASATINIB SRC inhibitor 4 - lymphoid leukemia EMA
SRC DASATINIB SRC inhibitor 4 - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive EMA
SRC VANDETANIB Tyrosine-protein kinase SRC inhibitor 4 Active, not recruiting thyroid cancer ClinicalTrials
SRC VANDETANIB Tyrosine-protein kinase SRC inhibitor 4 - medullary thyroid gland carcinoma DailyMed
SRC DASATINIB SRC inhibitor 3 Active, not recruiting acute lymphoblastic leukemia ClinicalTrials
SRC DASATINIB SRC inhibitor 3 Not yet recruiting acute lymphoblastic leukemia ClinicalTrials
SRC DASATINIB SRC inhibitor 3 Completed acute lymphoblastic leukemia ClinicalTrials
ClinicalTrials
SRC DASATINIB SRC inhibitor 3 Completed acute myeloid leukemia ClinicalTrials
SRC BOSUTINIB Tyrosine-protein kinase SRC inhibitor 3 Active, not recruiting chronic myelogenous leukemia ClinicalTrials
ClinicalTrials
SRC BOSUTINIB Tyrosine-protein kinase SRC inhibitor 3 Completed chronic myelogenous leukemia ClinicalTrials
ClinicalTrials
SRC BOSUTINIB Tyrosine-protein kinase SRC inhibitor 3 Not yet recruiting chronic myelogenous leukemia ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

PSRC1-Ser122
Cancer Intensity
BRCA -1.185
COAD
HGSC 2.064
ccRCC 0.294
GBM -0.099
HNSC -0.218
LUAD -0.355
LUSC -0.937
non_ccRCC
PDAC
UCEC 0.435
PSRC1-Ser175
Cancer Intensity
BRCA -0.059
COAD
HGSC 1.505
ccRCC
GBM 0.071
HNSC
LUAD
LUSC -1.295
non_ccRCC
PDAC
UCEC -0.221
PSRC1-Ser186
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.993
HNSC
LUAD 1.007
LUSC
non_ccRCC
PDAC
UCEC -0.014
PSRC1-Ser65
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.225
GBM -1.667
HNSC
LUAD -0.014
LUSC 0.495
non_ccRCC
PDAC
UCEC 0.961
PSRC1-Ser70
Cancer Intensity
BRCA
COAD
HGSC -1.984
ccRCC 0.948
GBM 0.213
HNSC 0.641
LUAD 0.328
LUSC -0.616
non_ccRCC
PDAC
UCEC 0.469
PSRC1-Ser98
Cancer Intensity
BRCA -0.707
COAD
HGSC
ccRCC
GBM 0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RSRC1-Ser167
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC -0.707
non_ccRCC
PDAC 0.707
UCEC
RSRC1-Ser179
Cancer Intensity
BRCA -0.707
COAD
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RSRC1-Ser48
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.389
HNSC -0.318
LUAD 1.351
LUSC -1.201
non_ccRCC -1.068
PDAC -0.277
UCEC 1.123
RSRC1-Ser5
Cancer Intensity
BRCA
COAD
HGSC 0.707
ccRCC
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RSRC1-Ser50
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.389
HNSC -0.318
LUAD 1.351
LUSC -1.201
non_ccRCC -1.068
PDAC -0.277
UCEC 1.123
RSRC1-Ser52
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.389
HNSC -0.318
LUAD 1.351
LUSC -1.201
non_ccRCC -1.068
PDAC -0.277
UCEC 1.123
RSRC1-Ser6
Cancer Intensity
BRCA
COAD
HGSC -1.922
ccRCC
GBM 0.423
HNSC 0.95
LUAD 0.44
LUSC -0.056
non_ccRCC
PDAC
UCEC 0.164
RSRC1-Ser61
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 1.031
HNSC -0.066
LUAD -0.965
LUSC
non_ccRCC
PDAC
UCEC
RSRC1-Tyr62
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC -0.011
LUAD -0.788
LUSC -0.616
non_ccRCC 1.414
PDAC
UCEC
RSRC2-Ser104
Cancer Intensity
BRCA -0.638
COAD -1.263
HGSC 2.405
ccRCC 0.145
GBM -0.256
HNSC -0.477
LUAD -0.416
LUSC -0.337
non_ccRCC 1.235
PDAC -0.276
UCEC -0.121
RSRC2-Ser105
Cancer Intensity
BRCA -1.216
COAD -0.74
HGSC 2.38
ccRCC 0.209
GBM -0.231
HNSC -0.278
LUAD -0.448
LUSC -0.273
non_ccRCC 1.276
PDAC -0.31
UCEC -0.368
RSRC2-Ser17
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RSRC2-Ser222
Cancer Intensity
BRCA -0.84
COAD -0.875
HGSC 0.375
ccRCC 0.393
GBM 2.166
HNSC 1.022
LUAD -0.274
LUSC -1.511
non_ccRCC -0.354
PDAC 0.022
UCEC -0.124
RSRC2-Ser27
Cancer Intensity
BRCA 0.519
COAD 0.108
HGSC -2.225
ccRCC 0.356
GBM
HNSC 0.143
LUAD 0.464
LUSC
non_ccRCC
PDAC
UCEC 0.636
RSRC2-Ser30
Cancer Intensity
BRCA
COAD 0.223
HGSC -2.235
ccRCC 0.43
GBM 0.713
HNSC 0.289
LUAD 0.359
LUSC
non_ccRCC
PDAC
UCEC 0.221
RSRC2-Ser32
Cancer Intensity
BRCA
COAD -0.022
HGSC -2.355
ccRCC
GBM 0.475
HNSC
LUAD 0.809
LUSC 0.414
non_ccRCC 0.563
PDAC 0.257
UCEC -0.141
RSRC2-Ser348
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.762
GBM 0.061
HNSC
LUAD 0.607
LUSC
non_ccRCC
PDAC
UCEC -1.431
RSRC2-Ser350
Cancer Intensity
BRCA -1.091
COAD
HGSC
ccRCC 1.094
GBM -1.363
HNSC
LUAD
LUSC 0.237
non_ccRCC
PDAC 0.746
UCEC 0.378
RSRC2-Ser376
Cancer Intensity
BRCA 0.218
COAD
HGSC 0.4
ccRCC 0.357
GBM -1.111
HNSC 1.08
LUAD -2.133
LUSC 0.533
non_ccRCC
PDAC 0.001
UCEC 0.656
RSRC2-Ser383
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM
HNSC
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
RSRC2-Ser384
Cancer Intensity
BRCA
COAD 0.81
HGSC -1.118
ccRCC
GBM
HNSC
LUAD 0.308
LUSC
non_ccRCC
PDAC
UCEC
RSRC2-Ser41
Cancer Intensity
BRCA
COAD -0.707
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
RSRC2-Ser43
Cancer Intensity
BRCA
COAD -0.707
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
RSRC2-Thr16
Cancer Intensity
BRCA
COAD -0.203
HGSC 1.134
ccRCC 0.322
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC -1.253
RSRC2-Thr220
Cancer Intensity
BRCA
COAD -0.748
HGSC 0.14
ccRCC -0.177
GBM
HNSC
LUAD 1.634
LUSC -0.848
non_ccRCC
PDAC
UCEC
SRC-Ser104
Cancer Intensity
BRCA
COAD
HGSC -0.451
ccRCC
GBM
HNSC -1.396
LUAD 1.411
LUSC 0.602
non_ccRCC -0.574
PDAC 0.408
UCEC
SRC-Ser17
Cancer Intensity
BRCA -1.429
COAD -0.769
HGSC 0.743
ccRCC
GBM -0.22
HNSC -0.371
LUAD -0.317
LUSC 1.789
non_ccRCC
PDAC 0.573
UCEC
SRC-Ser348
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.292
HNSC -0.681
LUAD 1.035
LUSC -0.727
non_ccRCC 1.622
PDAC -0.901
UCEC -0.639
SRC-Ser69
Cancer Intensity
BRCA
COAD 0.833
HGSC 0.458
ccRCC
GBM
HNSC 0.149
LUAD
LUSC
non_ccRCC
PDAC
UCEC -1.44
SRC-Ser70
Cancer Intensity
BRCA
COAD 1.337
HGSC -0.837
ccRCC
GBM
HNSC -0.69
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.19
SRC-Ser75
Cancer Intensity
BRCA
COAD 1.583
HGSC 0.94
ccRCC
GBM 0.247
HNSC -0.981
LUAD 0.836
LUSC -0.18
non_ccRCC -1.429
PDAC -0.893
UCEC -0.124
SRC-Thr74
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
SRC-Tyr419
Cancer Intensity
BRCA
COAD -0.413
HGSC 1.82
ccRCC -0.985
GBM
HNSC -0.869
LUAD
LUSC 0.833
non_ccRCC
PDAC -0.088
UCEC -0.297
SRC-Tyr439
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 1.434
GBM 0.42
HNSC -0.616
LUAD
LUSC -0.062
non_ccRCC -1.177
PDAC
UCEC
SRCAP-Ser1859
Cancer Intensity
BRCA -0.284
COAD -0.454
HGSC 2.917
ccRCC -0.276
GBM 0.199
HNSC -0.023
LUAD -0.683
LUSC -0.195
non_ccRCC -0.598
PDAC -0.158
UCEC -0.446
SRCAP-Ser1862
Cancer Intensity
BRCA
COAD -0.624
HGSC 2.093
ccRCC 0.034
GBM 0.067
HNSC -0.009
LUAD -0.733
LUSC
non_ccRCC
PDAC
UCEC -0.828
SRCAP-Ser1882
Cancer Intensity
BRCA -0.303
COAD
HGSC
ccRCC -0.039
GBM -0.984
HNSC -0.17
LUAD -1.238
LUSC 0.419
non_ccRCC 2.277
PDAC 0.103
UCEC -0.067
SRCAP-Ser2430
Cancer Intensity
BRCA -0.018
COAD -0.582
HGSC 2.616
ccRCC 0.155
GBM -0.095
HNSC -0.271
LUAD -1.061
LUSC -0.372
non_ccRCC -0.325
PDAC 0.794
UCEC -0.841
SRCAP-Ser250
Cancer Intensity
BRCA 0.686
COAD 1.003
HGSC -1.066
ccRCC -0.622
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
SRCAP-Ser257
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.449
GBM
HNSC 1.198
LUAD -0.76
LUSC
non_ccRCC
PDAC
UCEC -0.887
SRCAP-Ser258
Cancer Intensity
BRCA
COAD 1.447
HGSC -0.939
ccRCC
GBM 0.45
HNSC
LUAD -0.898
LUSC -1.409
non_ccRCC 0.492
PDAC -0.032
UCEC 0.888
SRCAP-Ser270
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.579
GBM
HNSC 1.155
LUAD -0.576
LUSC
non_ccRCC
PDAC
UCEC
SRCAP-Ser2725
Cancer Intensity
BRCA -1.354
COAD -0.183
HGSC -1.655
ccRCC 1.133
GBM 0.43
HNSC 0.533
LUAD
LUSC 0.408
non_ccRCC
PDAC 0.689
UCEC
SRCAP-Ser273
Cancer Intensity
BRCA
COAD 0.184
HGSC -0.173
ccRCC
GBM -1.335
HNSC
LUAD 0.079
LUSC 1.712
non_ccRCC
PDAC
UCEC -0.467
SRCAP-Ser274
Cancer Intensity
BRCA
COAD 0.183
HGSC -0.483
ccRCC
GBM -0.227
HNSC 2.33
LUAD -0.412
LUSC -0.43
non_ccRCC
PDAC -0.948
UCEC -0.013
SRCAP-Ser2782
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.145
GBM
HNSC 1.065
LUAD -0.919
LUSC
non_ccRCC
PDAC
UCEC
SRCAP-Ser2785
Cancer Intensity
BRCA
COAD -0.707
HGSC
ccRCC
GBM
HNSC
LUAD 0.707
LUSC
non_ccRCC
PDAC
UCEC
SRCAP-Ser2787
Cancer Intensity
BRCA -0.576
COAD 0.487
HGSC -2.456
ccRCC 0.33
GBM 0.487
HNSC -0.4
LUAD
LUSC 0.864
non_ccRCC -0.211
PDAC 0.824
UCEC 0.651
SRCAP-Ser2790
Cancer Intensity
BRCA -0.613
COAD 0.679
HGSC -2.293
ccRCC 0.629
GBM 0.613
HNSC -0.056
LUAD 0.928
LUSC
non_ccRCC -0.307
PDAC
UCEC 0.419
SRCAP-Ser2840
Cancer Intensity
BRCA
COAD
HGSC -0.707
ccRCC 0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
SRCAP-Ser2869
Cancer Intensity
BRCA -0.035
COAD -0.821
HGSC -0.085
ccRCC -0.089
GBM -0.185
HNSC -0.302
LUAD -0.568
LUSC -0.556
non_ccRCC 2.912
PDAC -0.275
UCEC 0.004
SRCAP-Ser3016
Cancer Intensity
BRCA -1.171
COAD -0.957
HGSC 2.079
ccRCC -0.097
GBM -0.078
HNSC -0.141
LUAD -0.569
LUSC -0.535
non_ccRCC 1.648
PDAC -0.008
UCEC -0.171
SRCAP-Ser3020
Cancer Intensity
BRCA 0.324
COAD -0.869
HGSC 2.211
ccRCC -0.69
GBM 0.059
HNSC -0.13
LUAD -0.035
LUSC
non_ccRCC
PDAC
UCEC -0.869
SRCAP-Ser3053
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD 0.707
LUSC -0.707
non_ccRCC
PDAC
UCEC
SRCAP-Ser3054
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD 0.707
LUSC -0.707
non_ccRCC
PDAC
UCEC
SRCAP-Ser3055
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD 0.707
LUSC -0.707
non_ccRCC
PDAC
UCEC
SRCAP-Ser3126
Cancer Intensity
BRCA 0.409
COAD
HGSC 2.002
ccRCC -1.204
GBM 0.585
HNSC 0.479
LUAD -0.398
LUSC 0.056
non_ccRCC -1.59
PDAC -0.006
UCEC -0.333
SRCAP-Ser3148
Cancer Intensity
BRCA -0.203
COAD -0.091
HGSC -1.464
ccRCC -0.158
GBM 0.158
HNSC -0.184
LUAD -0.003
LUSC -0.716
non_ccRCC 2.644
PDAC 0.341
UCEC -0.325
SRCAP-Ser3161
Cancer Intensity
BRCA
COAD 0.39
HGSC -1.96
ccRCC
GBM -0.09
HNSC 0.52
LUAD 0.375
LUSC
non_ccRCC
PDAC
UCEC 0.765
SRCAP-Ser3168
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC -0.514
LUAD -0.638
LUSC
non_ccRCC
PDAC
UCEC 1.152
SRCAP-Ser3172
Cancer Intensity
BRCA
COAD 0.281
HGSC -1.761
ccRCC
GBM
HNSC 0.61
LUAD 0.251
LUSC
non_ccRCC
PDAC
UCEC 0.619
SRCAP-Ser3177
Cancer Intensity
BRCA
COAD 0.105
HGSC -2.087
ccRCC
GBM 0.11
HNSC 0.291
LUAD
LUSC 1.205
non_ccRCC 0.106
PDAC
UCEC 0.269
SRCAP-Ser349
Cancer Intensity
BRCA
COAD
HGSC 0.707
ccRCC
GBM
HNSC -0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
SRCAP-Ser562
Cancer Intensity
BRCA 1.171
COAD -0.683
HGSC
ccRCC -0.323
GBM -0.248
HNSC -0.005
LUAD -1.051
LUSC -0.375
non_ccRCC 2.304
PDAC -0.143
UCEC -0.648
SRCAP-Ser568
Cancer Intensity
BRCA 1.073
COAD -0.215
HGSC -2.158
ccRCC -0.035
GBM 0.084
HNSC 0.201
LUAD -0.575
LUSC -0.074
non_ccRCC 1.912
PDAC 0.098
UCEC -0.311
SRCAP-Thr1863
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.839
GBM 1.106
HNSC -0.267
LUAD
LUSC
non_ccRCC
PDAC
UCEC
SRCAP-Thr256
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM
HNSC
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
SRCAP-Thr2724
Cancer Intensity
BRCA -1.438
COAD -0.672
HGSC 1.591
ccRCC 0.808
GBM 0.08
HNSC 0.149
LUAD -0.518
LUSC
non_ccRCC
PDAC
UCEC
SRCAP-Thr572
Cancer Intensity
BRCA 0.256
COAD -0.039
HGSC -2.8
ccRCC 0.318
GBM 0.552
HNSC 0.531
LUAD -0.141
LUSC -0.147
non_ccRCC 1.106
PDAC 0.374
UCEC -0.009
SRCAP-Tyr1885
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.535
GBM 1.499
HNSC -0.455
LUAD -0.51
LUSC
non_ccRCC
PDAC
UCEC
SRCIN1-Ser1003
Cancer Intensity
BRCA -1.083
COAD -0.381
HGSC -0.845
ccRCC 0.284
GBM -0.642
HNSC
LUAD -0.549
LUSC 0.093
non_ccRCC 2.393
PDAC 0.657
UCEC 0.072
SRCIN1-Ser1043
Cancer Intensity
BRCA -0.899
COAD
HGSC
ccRCC
GBM -0.83
HNSC
LUAD 0.806
LUSC
non_ccRCC
PDAC 0.923
UCEC
SRCIN1-Ser1060
Cancer Intensity
BRCA -1.188
COAD
HGSC
ccRCC
GBM -0.448
HNSC
LUAD 0.657
LUSC
non_ccRCC
PDAC 0.978
UCEC
SRCIN1-Ser1118
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.127
HNSC
LUAD 1.057
LUSC -0.931
non_ccRCC
PDAC
UCEC
SRCIN1-Ser1154
Cancer Intensity
BRCA
COAD
HGSC 0.707
ccRCC
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
SRCIN1-Ser1155
Cancer Intensity
BRCA -1.036
COAD 1.036
HGSC -0.195
ccRCC
GBM -0.85
HNSC
LUAD
LUSC 1.046
non_ccRCC
PDAC
UCEC
SRCIN1-Ser165
Cancer Intensity
BRCA 0.161
COAD 0.425
HGSC 0.852
ccRCC
GBM
HNSC
LUAD -1.438
LUSC
non_ccRCC
PDAC
UCEC
SRCIN1-Ser225
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC 0.707
UCEC
SRCIN1-Ser343
Cancer Intensity
BRCA -0.707
COAD 0.707
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
SRCIN1-Ser362
Cancer Intensity
BRCA -1.048
COAD
HGSC
ccRCC
GBM 1.012
HNSC
LUAD -1.027
LUSC
non_ccRCC
PDAC 0.89
UCEC 0.173
SRCIN1-Ser366
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.707
SRCIN1-Ser39
Cancer Intensity
BRCA -0.776
COAD
HGSC
ccRCC
GBM -0.352
HNSC
LUAD 1.128
LUSC
non_ccRCC
PDAC
UCEC
SRCIN1-Ser434
Cancer Intensity
BRCA
COAD 0.707
HGSC
ccRCC
GBM
HNSC
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
SRCIN1-Ser436
Cancer Intensity
BRCA
COAD 0.707
HGSC
ccRCC
GBM
HNSC
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
SRCIN1-Ser439
Cancer Intensity
BRCA
COAD 0.707
HGSC
ccRCC
GBM
HNSC
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
SRCIN1-Ser45
Cancer Intensity
BRCA -0.927
COAD 0.486
HGSC -1.276
ccRCC
GBM 1.005
HNSC 0.462
LUAD -1.665
LUSC 0.661
non_ccRCC
PDAC 0.452
UCEC 0.802
SRCIN1-Ser473
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.707
HNSC
LUAD 0.707
LUSC
non_ccRCC
PDAC
UCEC
SRCIN1-Ser474
Cancer Intensity
BRCA -0.707
COAD
HGSC
ccRCC
GBM 0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
SRCIN1-Ser493
Cancer Intensity
BRCA 1.14
COAD
HGSC
ccRCC
GBM -0.413
HNSC
LUAD -0.727
LUSC
non_ccRCC
PDAC
UCEC
SRCIN1-Ser513
Cancer Intensity
BRCA -1.137
COAD 1.224
HGSC
ccRCC 0.137
GBM -0.476
HNSC
LUAD -0.677
LUSC
non_ccRCC 1.774
PDAC -0.464
UCEC -0.38
SRCIN1-Ser517
Cancer Intensity
BRCA -0.727
COAD 0.474
HGSC 1.291
ccRCC
GBM -1.254
HNSC
LUAD -0.594
LUSC 0.81
non_ccRCC
PDAC
UCEC
SRCIN1-Ser522
Cancer Intensity
BRCA
COAD 0.712
HGSC
ccRCC
GBM -0.628
HNSC
LUAD -1.705
LUSC
non_ccRCC 0.998
PDAC 0.282
UCEC 0.34
SRCIN1-Ser551
Cancer Intensity
BRCA -1.046
COAD
HGSC
ccRCC
GBM
HNSC
LUAD 0.1
LUSC
non_ccRCC 0.946
PDAC
UCEC
SRCIN1-Ser64
Cancer Intensity
BRCA
COAD 0.634
HGSC 0.429
ccRCC -0.009
GBM -0.64
HNSC 0.405
LUAD -1.91
LUSC
non_ccRCC
PDAC
UCEC 1.092
SRCIN1-Ser842
Cancer Intensity
BRCA
COAD 0.281
HGSC
ccRCC 0.124
GBM -0.835
HNSC 1.68
LUAD -1.175
LUSC
non_ccRCC
PDAC
UCEC -0.075
SRCIN1-Ser844
Cancer Intensity
BRCA 1.148
COAD 0.497
HGSC
ccRCC
GBM -1.017
HNSC
LUAD -0.898
LUSC -0.978
non_ccRCC 1.535
PDAC 0.204
UCEC -0.491
SRCIN1-Ser866
Cancer Intensity
BRCA -1.035
COAD 0.19
HGSC 1.66
ccRCC -0.319
GBM -1.416
HNSC 0.691
LUAD -1.3
LUSC 0.029
non_ccRCC 1.198
PDAC 0.588
UCEC -0.286
SRCIN1-Ser875
Cancer Intensity
BRCA
COAD 0.707
HGSC
ccRCC
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
SRCIN1-Ser907
Cancer Intensity
BRCA -0.758
COAD
HGSC
ccRCC
GBM -0.671
HNSC
LUAD -0.745
LUSC 0.917
non_ccRCC
PDAC 1.257
UCEC
SRCIN1-Ser987
Cancer Intensity
BRCA -1.878
COAD 0.661
HGSC 0.223
ccRCC -0.252
GBM -0.272
HNSC 0.846
LUAD -1.081
LUSC -0.12
non_ccRCC 1.966
PDAC 0.154
UCEC -0.249
SRCIN1-Thr52
Cancer Intensity
BRCA
COAD
HGSC 0.707
ccRCC
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
SRCIN1-Thr596
Cancer Intensity
BRCA 0.957
COAD
HGSC
ccRCC
GBM -0.614
HNSC
LUAD -1.079
LUSC
non_ccRCC
PDAC 0.736
UCEC
SRCIN1-Thr609
Cancer Intensity
BRCA -0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC 0.707
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
Y 416 D Hepatocellular carcinoma/hepatocarcinoma/hepatoma Phosphorylation 24296779
Y 416 D Severe osteopetrosis Phosphorylation 23526378
Y 416 P Hepatocellular carcinoma/hepatocarcinoma/hepatoma Phosphorylation 24296779
Y 416 U Hepatocellular carcinoma/hepatocarcinoma/hepatoma Phosphorylation 23524339
Y 416 U Non-small cell lung cancer Phosphorylation 35131384
Y 416 U Ovarian cancer/carcinoma Phosphorylation 23277333
Y 416 U Prostate cancer Phosphorylation 36084759 17045208 17045208
Y 416 U Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 23145001

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: